| CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells W Liu, AL Putnam, Z Xu-Yu, GL Szot, MR Lee, S Zhu, PA Gottlieb, ... The Journal of experimental medicine 203 (7), 1701-1711, 2006 | 3508 | 2006 |
| The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes JM Wenzlau, K Juhl, L Yu, O Moua, SA Sarkar, P Gottlieb, M Rewers, ... Proceedings of the National Academy of Sciences 104 (43), 17040-17045, 2007 | 1296 | 2007 |
| Rituximab, B-lymphocyte depletion, and preservation of beta-cell function MD Pescovitz, CJ Greenbaum, H Krause-Steinrauf, DJ Becker, ... New England Journal of Medicine 361 (22), 2143-2152, 2009 | 1134 | 2009 |
| Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association RA Insel, JL Dunne, MA Atkinson, JL Chiang, D Dabelea, PA Gottlieb, ... Diabetes care 38 (10), 1964-1974, 2015 | 1057 | 2015 |
| Autoimmune polyendocrine syndromes GS Eisenbarth, PA Gottlieb New England Journal of Medicine 350 (20), 2068-2079, 2004 | 849 | 2004 |
| An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes KC Herold, BN Bundy, SA Long, JA Bluestone, LA DiMeglio, MJ Dufort, ... New England Journal of Medicine 381 (7), 603-613, 2019 | 798 | 2019 |
| Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial T Orban, B Bundy, DJ Becker, LA DiMeglio, SE Gitelman, R Goland, ... The Lancet 378 (9789), 412-419, 2011 | 605 | 2011 |
| Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial DK Wherrett, B Bundy, DJ Becker, LA DiMeglio, SE Gitelman, R Goland, ... The Lancet 378 (9788), 319-327, 2011 | 403 | 2011 |
| Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic … KC Herold, SE Gitelman, MR Ehlers, PA Gottlieb, CJ Greenbaum, ... Diabetes 62 (11), 3766-3774, 2013 | 398 | 2013 |
| Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells EM Bradshaw, K Raddassi, W Elyaman, T Orban, PA Gottlieb, SC Kent, ... The Journal of Immunology 183 (7), 4432-4439, 2009 | 340 | 2009 |
| Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data CJ Greenbaum, CA Beam, D Boulware, SE Gitelman, PA Gottlieb, ... Diabetes 61 (8), 2066-2073, 2012 | 326 | 2012 |
| Testing the NKT cell hypothesis of human IDDM pathogenesis PT Lee, A Putnam, K Benlagha, L Teyton, PA Gottlieb, A Bendelac The Journal of clinical investigation 110 (6), 793-800, 2002 | 322 | 2002 |
| Alterations in intestinal microbiota correlate with susceptibility to type 1 diabetes AK Alkanani, N Hara, PA Gottlieb, D Ir, CE Robertson, BD Wagner, ... Diabetes 64 (10), 3510-3520, 2015 | 301 | 2015 |
| No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes T Brusko, C Wasserfall, K McGrail, R Schatz, HL Viener, D Schatz, ... Diabetes 56 (3), 604-612, 2007 | 301 | 2007 |
| Autoantibody “subspecificity” in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups JM Barker, J Yu, L Yu, J Wang, D Miao, F Bao, E Hoffenberg, JC Nelson, ... Diabetes care 28 (4), 850-855, 2005 | 289 | 2005 |
| Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis–related diabetes: a technical review A Moran, D Becker, SJ Casella, PA Gottlieb, MS Kirkman, BC Marshall, ... Diabetes care 33 (12), 2677, 2010 | 281 | 2010 |
| B-lymphocyte depletion with rituximab and β-cell function: two-year results MD Pescovitz, CJ Greenbaum, B Bundy, DJ Becker, SE Gitelman, ... Diabetes care 37 (2), 453-459, 2014 | 280 | 2014 |
| CD4+ CD25high regulatory T cells in human autoimmune diabetes AL Putnam, F Vendrame, F Dotta, PA Gottlieb Journal of autoimmunity 24 (1), 55-62, 2005 | 276 | 2005 |
| Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes M Battaglia, S Ahmed, MS Anderson, MA Atkinson, D Becker, PJ Bingley, ... Diabetes care 43 (1), 5-12, 2020 | 269 | 2020 |
| Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients MR Rigby, KM Harris, A Pinckney, LA DiMeglio, MS Rendell, EI Felner, ... The Journal of clinical investigation 125 (8), 3285-3296, 2016 | 266 | 2016 |
